CHRS
Price
$0.87
Change
-$0.00 (-0.00%)
Updated
Jul 10 closing price
Capitalization
100.65M
20 days until earnings call
SLXN
Price
$0.82
Change
-$0.09 (-9.89%)
Updated
Jul 10, 04:59 PM (EDT)
Capitalization
7.91M
Interact to see
Advertisement

CHRS vs SLXN

Header iconCHRS vs SLXN Comparison
Open Charts CHRS vs SLXNBanner chart's image
Coherus Oncology
Price$0.87
Change-$0.00 (-0.00%)
Volume$1.1M
Capitalization100.65M
Silexion Therapeutics
Price$0.82
Change-$0.09 (-9.89%)
Volume$174
Capitalization7.91M
CHRS vs SLXN Comparison Chart in %
Loading...
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLXN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CHRS vs. SLXN commentary
Jul 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHRS is a StrongBuy and SLXN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 11, 2025
Stock price -- (CHRS: $0.87 vs. SLXN: $0.83)
Brand notoriety: CHRS and SLXN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CHRS: 81% vs. SLXN: 80%
Market capitalization -- CHRS: $100.65M vs. SLXN: $7.91M
CHRS [@Biotechnology] is valued at $100.65M. SLXN’s [@Biotechnology] market capitalization is $7.91M. The market cap for tickers in the [@Biotechnology] industry ranges from $314.48B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHRS’s FA Score shows that 0 FA rating(s) are green whileSLXN’s FA Score has 0 green FA rating(s).

  • CHRS’s FA Score: 0 green, 5 red.
  • SLXN’s FA Score: 0 green, 5 red.
According to our system of comparison, SLXN is a better buy in the long-term than CHRS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHRS’s TA Score shows that 4 TA indicator(s) are bullish while SLXN’s TA Score has 5 bullish TA indicator(s).

  • CHRS’s TA Score: 4 bullish, 3 bearish.
  • SLXN’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, CHRS is a better buy in the short-term than SLXN.

Price Growth

CHRS (@Biotechnology) experienced а +7.06% price change this week, while SLXN (@Biotechnology) price change was +1.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +10.19%. For the same industry, the average monthly price growth was +16.32%, and the average quarterly price growth was +20.67%.

Reported Earning Dates

CHRS is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+10.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CHRS($101M) has a higher market cap than SLXN($7.91M). CHRS YTD gains are higher at: -37.159 vs. SLXN (-58.910). CHRS has higher annual earnings (EBITDA): 80.2M vs. SLXN (-16.96M). CHRS has more cash in the bank: 82.4M vs. SLXN (6.15M). SLXN has less debt than CHRS: SLXN (3.48M) vs CHRS (270M). CHRS has higher revenues than SLXN: CHRS (272M) vs SLXN (0).
CHRSSLXNCHRS / SLXN
Capitalization101M7.91M1,277%
EBITDA80.2M-16.96M-473%
Gain YTD-37.159-58.91063%
P/E Ratio1.97N/A-
Revenue272M0-
Total Cash82.4M6.15M1,339%
Total Debt270M3.48M7,754%
FUNDAMENTALS RATINGS
CHRS: Fundamental Ratings
CHRS
OUTLOOK RATING
1..100
9
VALUATION
overvalued / fair valued / undervalued
1..100
90
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
63
P/E GROWTH RATING
1..100
96
SEASONALITY SCORE
1..100
11

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CHRSSLXN
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
60%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 2 days ago
41%
Momentum
ODDS (%)
Bullish Trend 1 day ago
70%
Bullish Trend 2 days ago
23%
MACD
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 2 days ago
25%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 2 days ago
26%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
70%
Bearish Trend 2 days ago
48%
Advances
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 4 days ago
51%
Declines
ODDS (%)
Bearish Trend 18 days ago
88%
Bearish Trend 24 days ago
73%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 2 days ago
20%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
61%
View a ticker or compare two or three
Interact to see
Advertisement
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SLXN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IDR16.182.81
+21.02%
Idaho Strategic Resources
SCKT1.240.04
+3.30%
Socket Mobile
POOL311.302.84
+0.92%
Pool Corp
CINT5.88-0.05
-0.84%
CI&T
NMIH38.59-1.43
-3.57%
NMI Holdings

CHRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CHRS has been loosely correlated with XENE. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if CHRS jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHRS
1D Price
Change %
CHRS100%
-0.12%
XENE - CHRS
40%
Loosely correlated
+0.92%
ADCT - CHRS
39%
Loosely correlated
+4.76%
ARRY - CHRS
39%
Loosely correlated
-0.78%
AXON - CHRS
38%
Loosely correlated
-9.04%
RXRX - CHRS
37%
Loosely correlated
+2.24%
More

SLXN and

Correlation & Price change

A.I.dvisor tells us that SLXN and QSI have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SLXN and QSI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLXN
1D Price
Change %
SLXN100%
-9.23%
QSI - SLXN
25%
Poorly correlated
-3.21%
CHRS - SLXN
24%
Poorly correlated
-0.12%
FBRX - SLXN
22%
Poorly correlated
-8.21%
ORIC - SLXN
20%
Poorly correlated
+5.05%
MTVA - SLXN
13%
Poorly correlated
+3.91%
More